ERBB2 and breast cancer: A retrospective study revealed that patients with HR+/HER2+, HR−/HER2+, and TNBC achieved higher breast and axillary pCR rates after NAC than patients with HR+/HER2 breast cancer, and PRSLN was lower (3.6%) in patients with breast pCR (33).